Latest From Nektar Therapeutics
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.
Latest effort by FDA to re-set reviews for novel opioid analgesics is off to a rocky start after three advisory committee reviews. One unintended consequences may already be apparent: by taking a broad, public health perspective on new formulations, the agency may be inviting arguments based on price.
US FDA's advisors produce tie vote on bupivacaine extended-release solution for post-surgical analgesia; proponents valued its potential to to cut opioid use, while opponents questioned its efficacy.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Immune Disorders
- Neurology, Nervous System
- Inhale Therapeutic Systems Inc.
- Nektar Therapeutics Inc.
- North America
- Parent & Subsidiaries
- Nektar Therapeutics
- Senior Management
Howard W Robin, Pres. & CEO
Gil M Labrucherie, SVP, CFO & COO
Stephen K Doberstein, PhD, SVP, R&D and Chief R&D Officer
John Northcott, Chief Commercial Officer
- Contact Info
Phone: (415) 482-5300
455 Mission Bay Blvd. S.
San Francisco, CA 94158
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.